192 related articles for article (PubMed ID: 34584911)
21. Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia.
Markusic DM; Herzog RW
J Genet Syndr Gene Ther; 2012 Jan; 1():1-9. PubMed ID: 23565343
[TBL] [Abstract][Full Text] [Related]
22. Baboon envelope pseudotyped lentiviral vectors efficiently transduce human B cells and allow active factor IX B cell secretion in vivo in NOD/SCIDγc
Levy C; Fusil F; Amirache F; Costa C; Girard-Gagnepain A; Negre D; Bernadin O; Garaulet G; Rodriguez A; Nair N; Vandendriessche T; Chuah M; Cosset FL; Verhoeyen E
J Thromb Haemost; 2016 Dec; 14(12):2478-2492. PubMed ID: 27685947
[TBL] [Abstract][Full Text] [Related]
23. In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice.
Gallo-Penn AM; Shirley PS; Andrews JL; Kayda DB; Pinkstaff AM; Kaloss M; Tinlin S; Cameron C; Notley C; Hough C; Lillicrap D; Kaleko M; Connelly S
Hum Gene Ther; 1999 Jul; 10(11):1791-802. PubMed ID: 10446919
[TBL] [Abstract][Full Text] [Related]
24. Complete short-term correction of canine hemophilia A by in vivo gene therapy.
Connelly S; Mount J; Mauser A; Gardner JM; Kaleko M; McClelland A; Lothrop CD
Blood; 1996 Nov; 88(10):3846-53. PubMed ID: 8916949
[TBL] [Abstract][Full Text] [Related]
25. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
Doering CB; Denning G; Shields JE; Fine EJ; Parker ET; Srivastava A; Lollar P; Spencer HT
Hum Gene Ther; 2018 Oct; 29(10):1183-1201. PubMed ID: 30160169
[TBL] [Abstract][Full Text] [Related]
26. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice.
Sarkar R; Mucci M; Addya S; Tetreault R; Bellinger DA; Nichols TC; Kazazian HH
Hum Gene Ther; 2006 Apr; 17(4):427-39. PubMed ID: 16610930
[TBL] [Abstract][Full Text] [Related]
27. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs.
Kay MA; Rothenberg S; Landen CN; Bellinger DA; Leland F; Toman C; Finegold M; Thompson AR; Read MS; Brinkhous KM
Science; 1993 Oct; 262(5130):117-9. PubMed ID: 8211118
[TBL] [Abstract][Full Text] [Related]
28. Onco-retroviral and lentiviral vector-based gene therapy for hemophilia: preclinical studies.
Van Damme A; Chuah MK; Collen D; VandenDriessche T
Semin Thromb Hemost; 2004 Apr; 30(2):185-95. PubMed ID: 15118930
[TBL] [Abstract][Full Text] [Related]
29. Gene therapy strategies for hemophilia: benefits versus risks.
Petrus I; Chuah M; VandenDriessche T
J Gene Med; 2010 Oct; 12(10):797-809. PubMed ID: 20848668
[TBL] [Abstract][Full Text] [Related]
30. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs.
Gallo-Penn AM; Shirley PS; Andrews JL; Tinlin S; Webster S; Cameron C; Hough C; Notley C; Lillicrap D; Kaleko M; Connelly S
Blood; 2001 Jan; 97(1):107-13. PubMed ID: 11133749
[TBL] [Abstract][Full Text] [Related]
31. Delivery of full-length factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A.
Matsui H; Fujimoto N; Sasakawa N; Ohinata Y; Shima M; Yamanaka S; Sugimoto M; Hotta A
PLoS One; 2014; 9(8):e104957. PubMed ID: 25126862
[TBL] [Abstract][Full Text] [Related]
32. Gene therapy for hemophilia.
Ponder KP
Curr Opin Hematol; 2006 Sep; 13(5):301-7. PubMed ID: 16888433
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models.
Markusic DM; Nichols TC; Merricks EP; Palaschak B; Zolotukhin I; Marsic D; Zolotukhin S; Srivastava A; Herzog RW
J Transl Med; 2017 May; 15(1):94. PubMed ID: 28460646
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic levels of human factor VIII in mice implanted with encapsulated cells: potential for gene therapy of haemophilia A.
García-Martín C; Chuah MK; Van Damme A; Robinson KE; Vanzieleghem B; Saint-Remy JM; Gallardo D; Ofosu FA; Vandendriessche T; Hortelano G
J Gene Med; 2002; 4(2):215-23. PubMed ID: 11933222
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
Shah J; Kim H; Sivamurthy K; Monahan PE; Fries M
Curr Med Res Opin; 2023 Feb; 39(2):227-237. PubMed ID: 36285399
[TBL] [Abstract][Full Text] [Related]
36. Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A.
Wang X; Shin SC; Chiang AF; Khan I; Pan D; Rawlings DJ; Miao CH
Mol Ther; 2015 Apr; 23(4):617-26. PubMed ID: 25655313
[TBL] [Abstract][Full Text] [Related]
37. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
[TBL] [Abstract][Full Text] [Related]
38. Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B.
Xu L; Gao C; Sands MS; Cai SR; Nichols TC; Bellinger DA; Raymer RA; McCorquodale S; Ponder KP
Blood; 2003 May; 101(10):3924-32. PubMed ID: 12531787
[TBL] [Abstract][Full Text] [Related]
39. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.
Finn JD; Ozelo MC; Sabatino DE; Franck HW; Merricks EP; Crudele JM; Zhou S; Kazazian HH; Lillicrap D; Nichols TC; Arruda VR
Blood; 2010 Dec; 116(26):5842-8. PubMed ID: 20876851
[TBL] [Abstract][Full Text] [Related]
40. Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene.
Staber JM; Pollpeter MJ; Anderson CG; Burrascano M; Cooney AL; Sinn PL; Rutkowski DT; Raschke WC; McCray PB
Gene Ther; 2017 Nov; 24(11):742-748. PubMed ID: 28905885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]